Elan has said that its revenue from continuing operations for the second three months of its financial year was $56.3 million.
In a statement today, the Irish pharmaceutical company said it ended the quarter with over $1.9 billion in cash and that its net loss from continuing operations was $251.8 million.
However its net income for the quarter was almost $2.29 billion, largely due to the revenue generated by its restructuring of its Tysabri collaboration with Biogen Idec.
In a statement chief executive Kelly Martin said: "We are focused squarely on the process of exploring a sale of the company as announced by our Board of Directors on June 14, 2013.”
He added that the board of directors and the company’s executive management “are in complete alignment with regard to exploring all opportunities to maximize shareholder value."
